Literature DB >> 16543068

Effect of 5-aza-2'-deoxycytidine (Dacogen) on covalent histone modifications of chromatin associated with the epsilon-, gamma-, and beta-globin promoters in Papio anubis.

Donald Lavelle1, Kestis Vaitkus, Maria Hankewych, Mahipal Singh, Joseph DeSimone.   

Abstract

OBJECTIVE: Treatment with the DNA demethylating drug 5-aza-2'-deoxycytidine (Dacogen; DAC) increased fetal hemoglobin and F cells to therapeutically significant levels in patients with sickle cell disease. To gain more insight into the mechanism of action of this drug and to increase our understanding of the relationship between DNA methylation and chromatin structure, we have determined the effect of DAC on covalent histone modifications of chromatin associated with the epsilon, gamma-, and beta-globin promoters in purified bone marrow erythroid cells of four baboons (P. anubis) pre- and posttreatment.
RESULTS: Fetal hemoglobin increased from 6.45%+/-1.75% in pretreatment samples to 62.1%+/-7.94% following DAC. DNA methylation of three CpG sites within the epsilon-globin promoter and 5 CpG sites within the gamma-globin promoter decreased more than 50% following DAC treatment. Levels of RNA polymerase II, acetyl-histone H3, acetyl-histone H4, dimethyl-histone H3 (lys4), dimethyl-histone H3 (lys36), and dimethyl-histone H3 (lys79) associated with the epsilon-, gamma-, and beta-globin promoters were determined by chromatin immunoprecipitation of formaldehyde-fixed chromatin followed by real-time PCR. Dacogen treatment increased the association of RNA polymerase II, acetyl-histone H3, and acetyl-histone H4 with the gamma-globin promoter but did not significantly affect the association of dimethyl-histone H3 (lys4), dimethyl-histone H3 (lys36), and dimethyl-histone H3 (lys79) with the epsilon-, gamma-, and beta-globin gene promoters.
CONCLUSION: These experiments illustrate the usefulness of the baboon model to investigate the mechanism of pharmacologic reactivation of fetal hemoglobin synthesis at the molecular level.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16543068     DOI: 10.1016/j.exphem.2005.12.010

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  18 in total

1.  Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.

Authors:  Donald Lavelle; Kestis Vaitkus; Yonghua Ling; Maria A Ruiz; Reda Mahfouz; Kwok Peng Ng; Soledad Negrotto; Nicola Smith; Pramod Terse; Kory J Engelke; Joseph Covey; Kenneth K Chan; Joseph Desimone; Yogen Saunthararajah
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

2.  siDNMT1 increases γ-globin expression in chemical inducer of dimerization (CID)-dependent mouse βYAC bone marrow cells and in baboon erythroid progenitor cell cultures.

Authors:  Virryan Banzon; Vinzon Ibanez; Kestis Vaitkus; Maria Armila Ruiz; Kenneth Peterson; Joseph DeSimone; Donald Lavelle
Journal:  Exp Hematol       Date:  2010-10-23       Impact factor: 3.084

3.  Inhibition of G9a methyltransferase stimulates fetal hemoglobin production by facilitating LCR/γ-globin looping.

Authors:  Ivan Krivega; Colleen Byrnes; Jaira F de Vasconcellos; Y Terry Lee; Megha Kaushal; Ann Dean; Jeffery L Miller
Journal:  Blood       Date:  2015-05-15       Impact factor: 22.113

4.  Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice.

Authors:  Pramod Terse; Kory Engelke; Kenneth Chan; Yonghua Ling; Douglas Sharpnack; Yogen Saunthararajah; Joseph M Covey
Journal:  Int J Toxicol       Date:  2014-03-17       Impact factor: 2.032

5.  Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia.

Authors:  Aisha L Walker; Shirley Steward; Thad A Howard; Nicole Mortier; Matthew Smeltzer; Yong-Dong Wang; Russell E Ware
Journal:  Blood       Date:  2011-09-14       Impact factor: 22.113

Review 6.  Advancements in the delivery of epigenetic drugs.

Authors:  Samantha A Cramer; Isaac M Adjei; Vinod Labhasetwar
Journal:  Expert Opin Drug Deliv       Date:  2015-03-05       Impact factor: 6.648

7.  Identification of a PRMT5-dependent repressor complex linked to silencing of human fetal globin gene expression.

Authors:  Gerhard Rank; Loretta Cerruti; Richard J Simpson; Robert L Moritz; Stephen M Jane; Quan Zhao
Journal:  Blood       Date:  2010-05-21       Impact factor: 22.113

8.  PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing.

Authors:  Quan Zhao; Gerhard Rank; Yuen T Tan; Haitao Li; Robert L Moritz; Richard J Simpson; Loretta Cerruti; David J Curtis; Dinshaw J Patel; C David Allis; John M Cunningham; Stephen M Jane
Journal:  Nat Struct Mol Biol       Date:  2009-02-22       Impact factor: 15.369

9.  S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis).

Authors:  Donald Lavelle; Yogen Saunthararajah; Kestis Vaitkus; Mahipal Singh; Virryan Banzon; Pasit Phiasivongsva; Sanjeev Redkar; Sarath Kanekal; David Bearss; Chongtie Shi; Roger Inloes; Joseph DeSimone
Journal:  J Transl Med       Date:  2010-10-08       Impact factor: 5.531

Review 10.  Epigenetics of beta-globin gene regulation.

Authors:  Christine M Kiefer; Chunhui Hou; Jane A Little; Ann Dean
Journal:  Mutat Res       Date:  2008-08-07       Impact factor: 2.433

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.